Tranexamic Acid
- Atc Codes:B02AA02
- CAS Codes:1197-18-8
- PHARMGKB ID:1197-18-8
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
Brand Names
Europe
Austria: Cyklokapron; Belgium: Exacyl; Cyprus: Azeptil, Tranexamic Acid; Czech Republic: Exacyl; Denmark: Cyklokapron; Estonia: Cyklokapron; Finland: Caprilon, Cyklokapron; France: Exacyl; Germany: Cyklokapron; Hungary: Exacyl; Ireland: Cyklokapron; Italy: Tranex, Ugurol; Latvia: Cyklokapron; Luxembourg: Exacyl; Malta: Cyklokapron, Tranexamic Acid; Netherlands: Cyklokapron; Poland: Exacyl; Romania: Exacyl; Spain: Amchafibrin; Sweden: Cyklo-f, Cyklokapron, Cyklonova, Tranexamsyra, Tranon; UK: Cyklokapron, Tranexamic Acid.
North America
Canada: Cyklokapron, Tranexamic Acid; USA: Cyklokapron, Lysteda.
Latin America
Brazil: Hemoblock, Transamin.
Asia
Japan: Hemlon, Hexatron, Keisamine, Nicolda, Pletasmin, Ranobis, Rikavarin, Tracapmin, Tranexan, Transabon, Transamin, Trasamlon, Vanarin Top, Youxamine.
Drug combinations
Tranexamic Acid and Protein C Concentrate (Human)
Chemistry
Tranexamic Acid: C~8~H~15~NO~2~. Mw: 157.21. (1) Cyclohexanecarboxylic acid, 4-(aminomethyl)-, trans-; (2) trans-4-(Aminomethyl)cyclohexanecarboxylic acid. CAS-1197-18-8 (1967).
Pharmacologic Category
Antihemorrhagic Agents; Hemostatics. Antihemophilic Agent. (ATC-Code: B02AA02).
Mechanism of action
Forms reversible complex which displaces plasminogen from fibrin resulting in inhibition of fibrinolysis. Also inhibits proteolytic activity of plasmin.
Therapeutic use
Short-term use (2-8 days) in hemophilia patients during and following tooth extraction to reduce or prevent hemorrhage.
Pregnancy and lactiation implications
Use with caution in pregnancy and lactation.
Unlabeled use
Has been used as alternative to aminocaproic acid for subarachnoid hemorrhage.
Contraindications
Acquired defective color vision, active intravascular clotting, subarachnoid hemorrhage, concurrent factor IX complex or anti-inhibitor coagulant concentrates.
Warnings and precautions
Use with caution in cardiovascular disease, in cerebrovascular disease and in renal impairment. When used for subarachnoid hemorrhage, ischemic complications may occur. Use with caution in thromboembolic disease (may increase risk of thrombosis).